Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04505839 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
A Phase 1 study, sponsored by ST Pharm Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04505839: Completed Phase 1 study, sponsored by ST Pharm Co..
NCT04505839 is a Phase 1 study that has completed, run by ST Pharm Co.. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04505839, a Phase 1 study, has completed, sponsored by ST Pharm Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
Primary Outcome
DLTs are defined as any of the following adverse events (AEs) that are possibly or probably related to the trial regimen occurring during Cycle 1
Interventions
- DRUG STP1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2023-03-07 |
| Phase | Phase 1 |
What the finished NCT04505839 record still lists
NCT04505839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which STP1002 is the first listed.
NCT04505839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04505839 about?
NCT04505839 is a clinical study titled "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors". This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
What is the current status of trial NCT04505839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-30. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT04505839?
The interventions under investigation include: STP1002 (DRUG).
Who is sponsoring clinical trial NCT04505839?
This trial is sponsored by ST Pharm Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04505839's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI